Table 6. Oral immunotherapy trial using anti-IgE treatment.
Study | Treatment | N | Age | Dose Achieved on Initial Escalation Day (mg protein) |
---|---|---|---|---|
Nadeau (2011)60 | Omalizumab + Milk OIT | 11 | 7–17 y | 9/11 (82%) reached 1000 mg (1992mg cumulative dose) |
Schneider (2013)65 | Omalizumab + Peanut OIT | 13 | 7–15 y | 13/13 (100%) reached 500mg (992mg cumulative dose) |
Bégin (2014)39 | Omalizumab + Multiple Allergen OIT | 25 | 4–15 y | 19/25 (76%) reached 1250mg in total (2380 mg cumulative dose) |